Share on LinkedInShare on LinkedIn

ARTICLE · 17 APRIL 2015

CJEU Clarifies Application Of The Specific Mechanism

Fieldfisher
Fieldfisher
Contributor
Fieldfisher

Fieldfisher

Fieldfisher is a European law firm with market-leading practices in many of the world’s most...

View firm profile
Explore more from Fieldfisher

A pharma case ruling has clarified the derogation of exhaustion of patent and SPC rights through the 'Specific Mechanism', explain Beatriz San Martin and Philip Bilney.

European UnionIntellectual Property

A pharma case ruling has clarified the derogation of exhaustion of patent and SPC rights through the 'Specific Mechanism', explain Beatriz San Martin and Philip Bilney:

On 12 February 2015, the Court of Justice of the European Union (CJEU) delivered its decision on the questions referred to it by the Court of Appeal in C-539/13 Merck Canada Inc, and Merck Sharp & Dohme Ltd v Sigma Pharmaceuticals plc on the interpretation of the Specific Mechanism, a provision which enables holders of patents and supplementary protection certificates (SPCs) of pharmaceutical products to prevent parallel imports of those products into the UK from certain new member states.

The decision provides useful guidance to owners or beneficiaries of patents and SPCs and to parallel importers as to the procedure under the Specific Mechanism and its enforceability.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from